number of access : ?
number of downloads : ?
ID 116353
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Obesity
Liraglutide
Semaglutide
Glucagon like peptide-1receptor agonists (GLP-1RAs)
Glucose-dependent insulinotropic polypeptide (GIP)
Content Type
Journal Article
Description
Obesity has been crucial diseases. Several agents have been used including Phentermine, Mazindol, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion and Liraglutide from 1959 to present. Glucagon like peptide-1receptor agonists (GLP-1RAs) has been used for type 2 diabetes mellitus (T2DM). As GLP-1RA, liraglutide is given 0.9 mg/day for T2DM, and 3.0 mg/day for obesity. Similary, semaglutide is given 1.0 mg/week for T2DM and 2.4 mg/week for obesity. Semaglutide brought 14.9% weight reduction for 68 weeks. There is a novel combination of GLP-1RA and glucose-dependent insulinotropic polypeptide (GIP) for treating obesity, which achieved at least 10% weight reduction in 6-39% of cases for 26 weeks.
Journal Title
Journal of Diabetes, Obesity & Metabolism
Publisher
Yumed Text
Volume
4
Issue
2
Start Page
e107
Published Date
2021-08-09
Rights
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences